Could less be more? shorter immunotherapy course tested for head and neck cancer
NCT ID NCT07373990
First seen Feb 01, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This study compares a shorter versus longer course of the immunotherapy drug tislelizumab, given alongside standard chemoradiotherapy, for people with advanced nasopharyngeal cancer. About 418 adults aged 18 to 65 with stage T4N1 or T1-4N2-3 disease will be randomly assigned to receive either 6 or 8 total doses of tislelizumab. The goal is to see if the shorter course is just as effective at preventing cancer from returning or spreading, while potentially reducing side effects and treatment burden.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.